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Abstract 
COPD is often accompanied by other chronic diseases that are also associated with systemic inflammation, such 
as obesity, diabetes, and arteriosclerosis. Recent data indicate that nocturnal oxygen desaturation and coexisting 
metabolic syndrome are related to systemic inflammation in patients with COPD. Alveolar hypoxia and conse-
quent hypoxemia increase in prevalence as COPD severity increases. Chronic hypoxemia contributes to the de-
velopment of adverse sequelae of COPD, such as pulmonary hypertension, atherosclerosis, lung microbiome di-
versity and systemic inflammation. COPD is a heterogeneous disease with airway inflammation driven by bacte-
rial infections, few studies to date they examined microbiology or infection. The introduction of culture-
independent techniques for the microbiological analysis of respiratory samples confirmed that respiratory system 
hosts a large number of microorganisms, which include a wide range of bacteria. Regular exposure to tobacco 
smoke, lifestyle and food pattern can change the microbiome in healthy smokers and at-risk COPD patients, in-
creasing the presence of a limited number of genres that reach a high relative abundance, a pattern, which can be 
considered as a dysbiosis. We assume that in patients with COPD and concurrent obesity and lung dysbiosis at 
least three factors play a role in the systemic inflammatory syndrome. Recent data showed that changes in the 
lung microbiome are associated with numerous exacerbations of COPD and are involved in mediating inflamma-
tory responses of the host in some patients. Further research should elucidate the complex relationship between 
obstructive lung disease, obesity and lung microbiome diversity systemic inflammation accompanying these dif-
ferent conditions, and the causative role of systemic inflammation in obese COPD with nocturnal oxygen desat-
uration. 
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Introduction 
Chronic obstructive pulmonary disease 
(COPD) is a disease associated with chronic in-
flammation of the airways and lung parenchy-
ma. (Faner and Agustí 2017) Yet, COPD is a 
complex, multi-component, heterogeneous dis-
ease, whose clinical, functional presentation 
greatly varies from patient to patient despite 
similar degree of airflow limitation. (Faner and 
Agustí 2017; Burgel et al. 2017) The current 
classification of airways disorders is imprecise 
with an overlap of phenotypes (e.g. asthma, 
chronic bronchitis and emphysema), resulting 
in difficulties of differentiating the disorders 
from one another. 
The prevalence, distribution and inter-
relationships of the main clinical and functional 
manifestations of the disease in a large, well-
characterised and controlled population of pa-
tients are lacking. Comorbidities such as chron-
ic heart failure, cardiovascular disease, depres-
sion, diabetes, muscle wasting, weight loss, lung 
cancer, and osteoporosis can frequently be 
found in patients with COPD and are consid-
ered part of the commonly prevalent non-
pulmonary sequelae of the disease. (Barnes and 
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Celli 2009, 1165–85; Chatila et al. 2008, 549–
55) Sleep-disordered breathing and COPD are 
among the most common pulmonary diseases. 
Nevertheless, the pathological mechanisms and 
clinical manifestations of COPD are not re-
stricted only to pulmonary inflammation and 
airway remodelling. In contrast, over the last 
decade, the recognition of COPD as a systemic 
disease has developed. (Barnes and Celli 2009, 
1165–85) 
Low-grade systemic inflammation can be de-
fined as a two- to fourfold elevation in circulat-
ing levels of proinflammatory and anti-
inflammatory cytokines, naturally occurring cy-
tokine antagonists, acute phase proteins, as well 
as minor increases in counts of neutrophil and 
natural killer cells. (Brüünsgaard and Pedersen 
2003, 15–39) Systemic inflammation is consid-
ered a hallmark of COPD and one of the key 
mechanisms that may be responsible for the in-
creased rate of comorbidities, including cardio-
vascular complications, cachexia and muscle 
dysfunction, osteoporosis, anaemia, clinical de-
pression and anxiety in COPD (Sin and Man 
2003, 1514–19)  
The human microbiota consists of 10-100 bil-
lion symbiotic microbial cells hosted by each 
person, mainly bacteria in the lung; the human 
microbiome is made up of the genes that these 
cells host (Turnbaugh et al. 2007, 804–10). 
These cells are likely to influence genetic influ-
ences outcomes of pulmonary disease and mi-
crobiota composition through the modulation 
of the host's defense mechanisms. 
There are few studies on genetic modifiers of 
exacerbation risk in COPD (Erb-Downward et 
al. 2011, e16384). 
We assume that in patients with obese COPD 
and diabetes mellitus type II both genes and 
lifestyle are influenced. All this is known, but 
the genes in the human microbiome also may 
play an important role in the systemic inflam-
matory syndrome: the severity of pulmonary 
impairment, the degree of obesity-related adi-
pose tissue hypoxia, and the severity of system-
ic hypoxia due to reduced pulmonary functions. 
The gut bacteria synthesize vitamins and pro-
teins and help degrade toxins. Many genes in 
the human microbiome produces hormones, 
neurotransmitters, cytokines and molecules of 
inflammation, which are released into the sys-
temic circulation and affect health. 
Recent evidence demonstrated that the micro-
biome might affect in the COPD patients in-
cluding patients with obesity and diabetes type 
II (Eduard Monsó 2017, 251). Exposure to to-
bacco smoke modifies the lung microbiome in 
healthy smokers, first in the oropharynx, in-
creasing the presence of a limited number of 
bacteria that reach a high concentration in the 
lower respiratory tract, a pattern that can be 
considered pathological as a dysbiosis pulmo-
nary. In the COPD, the microbiome analyzes 
of the sputum samples have shown an im-
portant change in bacterial diversity, with a var-
iation in a restricted flora with an over-
representation of the Proteobacteria strand, 
which includes most of the bacteria considered 
to be pathogenic microorganisms, together with 
a decrease of the relative abundance of micro-
organisms’ part of the phylum Firmicute-s. Se-
verity of COPD also influences degree of oxy-
gen desaturation and obesity and lifestyle. Sev-
eral data suggest that the pulmonary microbi-
ome plays a fundamental role during the exac-
erbations of COPD and its role in the aetiology 
of the disease remains poorly understood. 
This brief review focuses on COPD and noc-
turnal hypoxaemia with obesity and lung mi-
crobiome and dysbiosis that can be the cause of 
systemic inflammation and vascular atheroscle-
rosis. 
 
Systemic and airway inflammation 
Several studies have found markers of systemic 
inflammation, such as high-sensitivity C-
reactive protein (hs-CRP), to be higher in blood 
of patients with COPD when compared with 
the blood values of subjects without COPD. 
(Pinto-Plata et al. 2006, 23–28; Leonardo M 
Fabbri and Rabe 2007, 797–99).  A question 
arises whether systemic inflammation is the re-
sult of a local inflammation spill-over to the 
systemic compartments or a systemic compo-
nent of COPD not necessarily related to the lo-
cal inflammatory processes in the lung. (L M 
Fabbri et al. 2008, 204–12; Broekhuizen et al. 
2006, 17–22) 
As a point of interest, it should be noted that 
systemic inflammation has failed, so far, to 
show substantial correlations with airway ob-
struction, (de Torres et al. 2006, 902–7; Watz et 
al. 2009, 1039–46) whereas a connection has 
been reported between local inflammatory pro-
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cesses and airway obstruction. (Peleman et al. 
1999, 839–43; Turato et al. 2002, 105–10; Bar-
aldo et al. 2004, 308–12) Markers of systemic 
inflammation have been shown to be elevated 
in blood of patients with COPD when com-
pared with control subjects without COPD. 
COPD is often accompanied by other chronic 
diseases that are also associated with systemic 
inflammation, such as chronic heart failure, di-
abetes, and arteriosclerosis. (Roy et al. 2009, 41) 
Alternatively, increased levels of inflammatory 
mediators in the blood of COPD patients may 
stem from extra pulmonary cells (circulating 
leukocytes, endothelium or muscle cells). A par-
ticular problem in COPD patients with marked 
alveolar wall destruction is intermittent and 
continuous hypoxia. Significant inverse correla-
tion between arterial oxygen tension (PaO2) and 
circulating tumor necrosis factor alpha (TNF-a) 
and soluble tumor necrosis factor receptor 
(sTNF-R) levels in patients with COPD has 
been reported. (Takabatake et al. 2000, 1179–
84) Similarly, a significant relationship between 
reduced oxygen delivery and TNF-levels in the 
peripheral circulation, highlighting the role of 
nocturnal hypoxia of the tissue was found (Yu 
et al. 1998, L818-26)  
It has been suggested that systemic inflamma-
tion may explain part of the heterogeneity of 
COPD phenotypes, such as loss of lean body 
mass and the higher prevalence of co morbid 
disorders such as coronary heart disease 
(CHD), depression and hypertension. Finally, 
this study reinforces the view that systemic in-
flammation is an important phenotypic feature 
of COPD (Eagan et al. 2010, 540–48). Future 
prospective studies should investigate whether 
these markers will give important prognostic 
information in relation to disease progression 
and severity in COPD.  
 
Sleep disturbance in COPD 
COPD alone can cause subjective and objective 
changes during sleep. When patients with either 
chronic bronchitis or emphysema were sur-
veyed across a broad range of symptoms, “sleep 
difficulties” were endorsed as occurring “almost 
always” or “always” in 43% of subjects (third 
most common, after dyspnoea and fatigue). 
(Kinsman et al. 1983, 755–61) More than just 
the diagnosis of COPD, the presence of COPD 
symptoms such as cough or sputum production 
or wheezing strongly correlated with difficulty 
in falling or staying asleep.(Klink, Dodge and 
Quan 1994, 151–54) Other investigations have 
objectively confirmed poor sleep quality, with 
decreased total sleep-time and decreased sleep 
efficiency. (Douglas et al. 1982, 840–44). A 
brief review of the normal changes in respira-
tion that occur with sleep onset and the various 
sleep stages is useful to understand the changes 
occurring during sleep in patients with COPD. 
In healthy subjects, minute ventilation drops 
from wakefulness to non-rapid-eye-movement 
(non-REM) sleep, and drops further during 
REM sleep (about 15%,compared to the awake 
value) (Douglas et al. 1982, 286–89). Most of 
the drop in minute ventilation is due to a de-
crease in tidal volume not fully compensated by 
a concomitant increase in respiratory rate. 
There is a blunted ventilatory response to hy-
poxia and hypercapnia, again with the greatest 
changes during REM sleep. (Douglas et al. 
1982, 758–62) Sleep-related hypoventilation has 
been demonstrated in COPD, particularly dur-
ing REM sleep, with associated oxygen desatu-
ration. (Hudgel et al. 1983, 669–77). 
 Nocturnal oxygen desaturation in COPD is 
likely to be the consequence of the combined 
effects of physiological hypoventilation during 
sleep. However, there is evidence that some pa-
tients with awake PaO2 levels in the mildly hy-
poxaemic range can also develop clinically sig-
nificant nocturnal oxygen desaturation, which 
may predispose to pulmonary hypertension. 
(Fletcher et al. 1987, 604–8)  
Finally, possible mechanisms responsible for 
this reduction include respiratory muscle hypo-
tonia, cephalic displacement of the diaphragm 
and a decrease in lung compliance. (Johnson 
and Remmers 1984, 1011–17). 
 
Sleep-related breathing disturbances: noc-
turnal oxygen desaturation and alveolar 
hypoventilation. 
Sleep-related hypoventilation has been demon-
strated in COPD, particularly during REM, 
with associated oxygen desaturation (Hudgel et 
al. 1983, 669–77) There is a close relationship 
between the awake arterial oxygen tension PaO2 
and nocturnal oxygen saturation SatO2 levels, 
(Connaughton et al. 1988, 341–44) although 
hypercapnia is associated with a more pro-
nounced nocturnal oxygen desaturation than 
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normocapnia for any given level of waking 
SatO2 .(Bradley et al. 1990, 308–12)  
Nocturnal hypoxemia has been defined as a 
SatO2 of ≤ 90% for at least 5 min with a Nadir 
SatO2 of ≤ 85%. Time in bed has been defined 
as the time from the start to the end of the re-
cording. The percentage of total recording time 
(TRT) has been defined as the time spent in 
bed -- sleep latency + intrasleep wakefulness. 
The TRT spent in bed with a SatO2≤ of 90% 
has been defined as the T90%. The minimal 
TRT required for a satisfactory analysis of noc-
turnal recordings was/has been 2 hours. COPD 
patients with a T90 ≥ of 30% and a Nadir SatO2 
of 85% have been defined as Desaturators (D) 
and the others as Non-Desaturators (ND). 
(Toraldo et al. 2005, 3828–37) In this study the 
authors, as revealed by cluster analysis, have 
shown that clinical parameter predictors when 
awake from nocturnal desaturation were differ-
ent. COPD D patients may be identified by a 
clinical pattern of variables T90, Mean Pressury 
Artery Pulmonary (MPAP), and PaCO2 values, 
rather than by T90 alone, with the latter two var-
iables being predictors of nocturnal desatura-
tion severity. This study has revealed the com-
plexity of the nocturnal desaturation that many 
clinical variables describe not only as respirato-
ry when awake. Alveolar hypoventilation prob-
ably accounts for most of the oxygen desatura-
tion. Becker and colleagues (Becker et al. 1999, 
112–18) measured minute ventilation during 
wakefulness, non-REM sleep, and REM sleep 
in normal subjects and patients with COPD. 
The greater drop in minute ventilation in sub-
jects with COPD may reflect increased depend-
ence on accessory muscles that become hypo-
tonic during sleep, particularly during REM 
sleep. 
An alternative explanation comes from the 
work by O’ Donoghue and colleagues 
(O’Donoghue et al. 2004, 663–73) who have 
found an even greater drop in minute ventila-
tion during non-REM sleep in hypercapnic 
COPD patients. 
 
 
 
 
Clinical impact of nocturnal oxygen desatu-
ration  
The exact prevalence of Pulmonary Hyperten-
sion (PH) in patients with COPD is unclear. 
(Naeije 2005, 20–22) PH is a complication of 
advanced COPD observed in patients who 
show severe longstanding hypoxaemia. Even if 
PH is generally mild to moderate in most 
COPD patients, it may markedly worsen during 
acute exacerbations, sleep and exercise and 
these acute increases in PH could facilitate the 
development of right heart failure. (RHF) The 
diagnosis of PH in COPD patients is difficult. 
The published studies differ not only in their 
definition but also for conditions under which 
PH has been reported (rest, exercise, and exac-
erbation). According the European Society 
Cardiology and European Respiratory Society 
(Galie et al. 2009, 1219–63) PH has been de-
fined as an increase in mean pulmonary arterial 
pressure PAP ≥ 25 mmHg at rest as assessed 
by right heart catheterisation. (RCH) The defi-
nition of PH on exercise as a Pulmonary Artery 
Pressure (PAP) ≥ 30 mmHg as assessed by 
RHC is not supported by published data and 
healthy individuals can reach much higher val-
ues. 
The incidence of PH in COPD patients has 
been evaluated by Kessler and colleagues. 
(Kessler et al. 2001, 219–24) The authors have 
performed a longitudinal study on 131 patients 
with COPD by performing serial RHC at base-
line and then at follow-up (mean follow-up was 
6.8 ± 2.9 years). All subjects have had normal 
mean PAP at rest (≤ 20 mm Hg). They have 
been divided into two groups based on pres-
ence or absence of elevated mean PAP with ex-
ercise (≥30 mm Hg) 25% of patients developed 
PH on follow up and was mild by hemodynam-
ic criteria (mean PAP 26.8 ± 6.6 mm Hg). Sub-
jects who showed elevated PH with exercise 
were more likely to exhibit resting mean PAP 
elevation upon follow up. The rate of progres-
sion was +0.4 mm Hg per year.  
Nocturnal oxygen desaturation seems to con-
tribute to the development of PH; even in the 
absence of significant awake hypoxemias. 
(Fletcher et al. 1989, 757–64) REM-associated 
falls in SatO2 are associated with increases in 
pulmonary artery pressure during sleep that can 
be reversed by supplemental oxygen, although 
most COPD patients with sustained pulmonary 
hypertension are also hypoxaemic during the 
daytime. Various arrhythmias are also reported 
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during episodes of nocturnal desaturation. 
(Douglas et al. 1982, 758–62) These conse-
quences might help to explain why nocturnal 
oxygen desaturation is a marker of increased 
mortality, and why COPD patients are reported 
to die more frequently at night than expected 
(W T McNicholas and Fitzgerald 1984, 878)  
Tissue hypoxia is another mechanism that can 
contribute to systemic inflammation in COPD. 
In a clinical study (Yu et al. 1998, L818-26) it 
has been shown that TNF-a and receptor levels 
were significantly higher in patients with 
COPD, but significantly correlated with the se-
verity of arterial hypoxaemia. These results sug-
gest that arterial hypoxaemia in COPD is asso-
ciated with activation of the TNF-a system in 
vivo. 
The systemic effects of inflammation may sig-
nificantly contribute not only to respiratory ab-
normalities, symptoms and functional impair-
ment (e.g. exercise intolerance) associated with 
COPD but also to its chronic marked changes 
of vasomotor and endothelial function as pul-
monary vascular disease (Mal 2007, 114–19) 
The nocturnal desaturation–reoxygenation se-
quence is a typical pattern coupled with the ma-
jority of respiratory events. This sequence, de-
fining intermittent hypoxia (IH), leads to oxida-
tive stress, with production of reactive oxygen 
species. (ROS) (Lavie 2003, 35–51) Hypoxia in-
duced pulmonary vasoconstriction is a protec-
tive response to keep ventilation-perfusion ratio 
optimum by shunting blood away from the hy-
poxemic areas. The traditional hypoxic model 
of PH is based on the hypothesis that chronic 
hypoxia initiates vascular remodelling leading to 
permanent changes in pulmonary vasculature. 
Studies performed in vitro elucidated the mech-
anisms underlying hypoxia driven vascular 
changes. Barbera et al., (Barberà et al. 1994, 
423–29) have evaluated COPD patients under-
going lung resection and demonstrated that 
vascular changes contribute to vascular remod-
elling and reputedly may have an effect on vas-
cular dynamics leading to PH. Nocturnal hy-
poxia may induce endothelial cells to release 
proliferate cytokine leading to cellular hyper-
trophy in the vessel wall and increase in extra 
cellular matrix. In conclusion, the nocturnal hy-
poxic insult occurring during sleep-disordered 
breathing may also contribute to chronic vascu-
lar remodelling; these mechanisms generate 
vascular endothelial damage and dysfunction 
increasing the risk of pulmonary hypertension 
in COPD. (Jyothula and Safdar 2009, 351–63) 
The review by Mc Nicholas shows how disease 
act through similar pathways to cause cardio-
vascular disease. (Walter T McNicholas 2009, 
692–700) Another intriguing possibility report-
ed in that study is that nocturnal desaturation in 
COPD may contribute to an increased inci-
dence of COPD exacerbations, which may ac-
celerate lung-function decline and be associated 
with greater mortality (Donaldson et al. 2002, 
847–52; Soler-Cataluña et al. 2005, 925–31).  
 
Interaction of COPD and Obesity in Sys-
temic Inflammation 
Recently, the concept of systemic inflammation 
as a consequence of spill over of inflammatory 
mediators from the lungs to the systemic com-
partment in COPD has been broadly discussed. 
(Chung and Adcock 2008, 1334–56; van Eeden 
and Sin 2008, 224–38; Kim, Rogers and Criner 
2008, 478–85) Several factors likely play a role 
in the genesis of systemic inflammation of 
COPD. These include tobacco use, airway in-
flammation, airflow obstruction, and hyperin-
flation. However, an independent role for tissue 
hypoxia seems likely. (Agusti 2005, 367–70)  
The transcription factor nuclear factor κB 
(NFκB) is the master regulator of cellular in-
flammatory responses, controlling expression 
of key inflammatory cytokines, such as tumor 
necrosis factor alpha (TNFα) and interleukin-8. 
(Garvey, Taylor and McNicholas 2009, 1195–
1205) Evidence of a role for hypoxia in the in-
duction of an NFκB response comes from in 
vitro, in vivo, and clinical studies. Intermittent 
hypoxia is classically seen in patients with ob-
structive sleep apnea syndrome, but may arise 
in COPD, particularly during sleep or exertion. 
In sustained hypoxia, NFκB appears to interact 
with HIF-1α to promote the expression of in-
flammatory genes, such as cyclo-oygenase II. 
(Fitzpatrick et al. 2011, 1091–96)  
Similarly, in a rodent model, 24 hours of sus-
tained hypoxia has been shown to up regulate 
NFκB activity in pulmonary and cardiac tissue. 
(Fitzpatrick et al. 2011, 1091–96) Meanwhile, 
clinical studies in COPD patients have found 
that circulating levels of TNFα and soluble 
TNF receptors increase as arterial oxygen ten-
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sion decreases. (Takabatake et al. 2000, 1179–
84).  
A number of studies have suggested it may re-
sult from “overspill” of inflammatory mediators 
from the lungs and pulmonary circulation, 
while others have failed to find any correlation 
between measurable pulmonary and circulating 
inflammatory mediators. (Sinden and Stockley 
2010, 930–36) One potentially important 
source of inflammation in 
obese patients with COPD with nocturnal hy-
poxaemia is white adipose tissue. In patients 
with COPD, obesity is characterized by an ab-
solute abundance of fat mass (FM), similar to 
other diseases associated with excessive adiposi-
ty. The prevalence of obesity is the highest 
among patients with milder forms of the dis-
ease (GOLD Stages 1 and 2), and the lowest in 
patients with the most severe lung function im-
pairment in Stage 4. (Sin and Man 2003, 1514–
19; M Poulain et al. 2008, 35–41)  Marquis et al. 
(Marquis et al., 226-32-4) demonstrated the 
presence of one or more components of the 
metabolic syndrome in almost 50% of COPD 
patients. High adiposity and fat tissue accumu-
lation impair pulmonary functions and exercise 
performance. (Magali Poulain et al. 2006, 1293–
99) Obesity and the presence of metabolic syn-
drome are related to increased insulin resistance 
in overweight and obese COPD patients (Bol-
ton et al. 2007, 121–26) 
The study by Bolton et al. (Bolton et al. 2007, 
121–26) suggests that insulin resistance is ag-
gravated by both, high BMI and increases in 
circulatory inflammatory mediators such as IL-6 
in these patients. Indeed, inflammatory media-
tors TNF-α, IL-6, and leptin were significantly 
higher while plasma adiponectin levels were re-
duced in the presence of excess weight in 
COPD patients. Chronic low-grade adipose tis-
sue inflammation in obesity may represent a 
specific response to relative hypoxia of adiposi-
ties. (Trayhurn and Wood 2004, 347–55) Sever-
al factors may contribute to cell hypoxia within 
adipose tissue in association with high adiposi-
ty: (a) blood flow per unit adipose tissue mass is 
reduced in obese humans resulting in decreased 
blood supply to the tissue; (b) large adipocytes 
are further from the vasculature than the nor-
mal diffusion distance for O2. 
Adipocyte tissue hypoxia has detrimental ef-
fects on cell metabolism and function, as evi-
denced by studies in 
vitro and animal models. Studies in vitro have 
shown that hypoxia results in enhanced TNF-α 
production, increased expression of PAI-1, and 
reduced adiponectin and peroxisome prolifera-
tors-activated receptor gamma (PPARγ) expres-
sion (Chen et al. 2006, 549–56; Hosogai et al. 
2007, 901–11)  
On the other hand, however, obesity-related 
hypoxia evokes local inflammatory response 
within adipose tissue per se, and systemic hy-
poxia likely contributes to the adipose tissue in-
flammation. If so, elevated circulating levels of 
inflammation-related proteins may reflect also 
spill over from the adipose tissue to the system-
ic circulation in patients with COPD and con-
current obesity. 
Even in the absence of COPD, obesity is asso-
ciated with small airways dysfunction, decreased 
chest wall 
compliance, V/Q mismatch, and increased pe-
ripheral oxygen consumption, all potentially 
leading to relative hypoxemia. Risk of sleep-
disordered breathing and consequent nocturnal 
hypoxemia correlates with the degree of obesi-
ty, (Young et al. 1993, 1230–35) and in extreme 
cases, morbid obesity can lead to profound al-
veolar hypoventilation, with chronic hypercap-
nic respiratory failure. Dysregulated ventilatory 
control is another factor contributing 
to the occurrence and persistence of hypoxemia 
in COPD patients (Kessler et al. 2001, 369–76) 
 
The lung microbiome diversity plays an 
important role in COPD exacerbations: mi-
crobiota study.  
The introduction of bacterial culture techniques 
for the microbiological analysis of respiratory 
samples confirmed that the respiratory system 
hosts many microorganisms (microbiome), in-
cluding bacteria, viruses and broad-spectrum 
fungi. Studies using culture-independent tech-
niques such as PCR amplification and sequenc-
ing the ribosomal RNA 16 (R) 16S gene have 
investigated a distinct bacterial community in 
the airways of COPD patients compared to 
healthy subjects and suggest that changes in the 
microbiota pulmonary disease could be associ-
ated with inflammation and airway exacerba-
tions and disease progression. However, most 
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studies on pulmonary microbiome involved 
small groups of subjects with limited longitudi-
nal sampling and modest clinical information. 
(Huang et al. 2014, 2813–23; Zakharkina et al. 
2013, e68302) Acute exacerbations of COPD 
are a rapid worsening of symptoms in which 
the role of bacteria is one of the major etiologi-
cal factors (E Monsó et al. 1995, 1316–20; Soler 
et al. 1998, 1498–1505) Then, the dynamics of 
bacterial prevalence during exacerbations and 
its role in the pathogenesis of the disease re-
main poorly known. 
Most of the studies on COPD lung microbiota 
have used sputum as a representative sample of 
the respiratory system, thanks to its easy recov-
ery and standardized processing procedure. In 
the respiratory microbiome analysis, it should 
be considered that the sputum comes mainly 
from the proximal airways, which possess a flo-
ra that showed clear differences with the mi-
crobial pattern found in the distal bronchi and 
in the alveolar space (Cabrera-Rubio et al. 2012, 
3562–68; Pragman et al. 2012, e47305) which is 
studied on the contrary through bronchial bi-
opsies, and / or bronchoalveolar lavage, while 
in COPD the microbial diversity model has 
been shown to be different between the micro-
biological examination of the sputum (upper 
airways) and the microbiological examination 
coming from the distal samples (lower airways), 
a finding that confirms the differences between 
proximal and distal bronchial flora. Microbial 
cultures have correlated respiratory symptoms 
in COPD exacerbations to the detection of new 
strains in bronchial flora (Sethi and Murphy 
2008, 2355–65) but this change in bacterial flo-
ra does not occur in all disease exacerbations. 
The microbiome analyzes show a high relative 
abundance of specific bacterial genera, which 
can be considered etiological, for most exacer-
bations, while the remaining bacterial flora does 
not change significantly (Millares et al. 2014, 
1101–11; Dy and Sethi 2016, 196–202) Fur-
thermore, exacerbations are not only related to 
the prevalence of isolated bacterial genes, but 
are also associated with changes in the compo-
sition of the microbiome as a whole, but not 
always identifiable through the measurement of 
the relative infectious microbial load 
(Molyneaux et al. 2013, 1224–31). 
An increase in the relative abundance of a spe-
cific bacterial genus can be considered causal in 
a COPD, but often subsequently, it is not con-
firmed by culture results. Several studies have 
showed that bacteria prevalent in the analysis of 
bronchial secretions may not be confirmed by 
the examination of the culture, while the mi-
croorganisms of the culture grow easily from 
the sample analysed, although their relative 
abundance has not changed compared to the 
previous stability (Sethi et al. 2006, 991–98; Mil-
lares et al. 2014, 1101–11) The microbiome 
analyses demonstrated a different pattern in in-
fectious and eosinophilic exacerbations, with a 
clear prevalence of the Firmicutes genus in eo-
sinophilic exacerbation, in the face of the pre-
dominance of Proteobacteria in exacerbations 
that show positive cultures for bacteria (Wang 
et al. 2016, 1082–92) This finding supports the 
clinical characterization of exacerbations in 
these two categories (bacterial and eosino-
philic), considering that their microbial pattern 
is completely different and will require different 
therapeutic approaches. The interaction be-
tween different bacterial microorganisms can be 
addressed through analysis of microbiomes and 
in a clinical model; an important role of viral 
infection on the composition of the microbi-
ome in patients with COPD has been demon-
strated. Induced rhinovirus infection showed 
no effect on the microbiome of bronchial se-
cretions in healthy subjects, but was associated 
with an increase in the prevalence of Proteo-
bacteria in patients with COPD (Molyneaux et 
al. 2013, 1224–31). This observation confirms 
the role of rhinovirus infection as an inducer of 
changes in respiratory bacterial flora with 
prevalence of Proteobacteria and justifies the 
virus-virus detection of coinfections in one 
quarter of COPD exacerbations (Papi et al. 
2006, 1114–21) The presence of bacterial diver-
sity, often related to a relative increase in the 
bacterium Proteobacteria, is associated with 
greater severity in COPD and may be one of 
the determinants influencing the progression of 
exacerbations and pulmonary disease, as previ-
ously demonstrated in idiopathic pulmonary fi-
brosis (Molyneaux and Maher 2013, 376–81).  
 
Conclusion 
The hypoxic insult occurring during sleep-
disordered breathing to COPD varies from one 
condition to another. However, there are com-
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mon cardiovascular and metabolic morbidities 
in these various conditions 
There are major differences with continuous 
hypoxia, suggesting specific pathways originat-
ing from the occurrence of oxidative stress and 
inflammatory cascade activation. Nocturnal hy-
poxaemia during sleep and diurnal hypoxaemia 
seems to be the major factor in morbidity. Also, 
the hypothesis that adipose tissue may contrib-
ute to the overall systemic inflammatory pheno-
type in patients with early stages COPD with 
obesity or relative abundant fat mass is novel 
(Millares et al. 2014, 1101–11). The recent role 
played by the lung microbiota in systemic in-
flammation is been presented. The microbial 
composition of the lung bacterial flora in 
COPD has been studied through microbiome 
analysis, the involvement of respiratory flora in 
the pathogenesis of the disease, it is practically 
unknow. In conclusion, recent data showed that 
lung microbiota is dynamic in which rapid 
changes appeared to be associated with exacer-
bations and disease progression events indica-
tive of specific exacerbation phenotypes.  
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